Tauroursodeoxycholate (sodium)

• Description:

  Tauroursodeoxycholate (Tauroursodeoxycholic acid; TUDCA) sodium is an endoplasmic reticulum (ER) stress inhibitor. Tauroursodeoxycholate significantly reduces expression of apoptosis molecules, such as caspase-3 and caspase-12. Tauroursodeoxycholate also inhibits ERK.

• Product Name Alternative:

  Tauroursodeoxycholic acid (sodium) ; TUDCA (sodium) ; UR 906 (sodium)

• UNSPSC:

  12352211

• Hazard Statement:

  H302, H315, H319, H335

• Target:

  Apoptosis; Caspase; Endogenous Metabolite; ERK

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; MAPK/ERK Pathway; Metabolic Enzyme/Protease; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/Tauroursodeoxycholate-Sodium.html

• Concentration:

  10mM

• Purity:

  98.40

• Solubility:

  DMSO : 100 mg/mL (ultrasonic) |H2O : 100 mg/mL (ultrasonic)

• Smiles:

  C[C@H](CCC(NCCS(=O)(O[Na])=O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])CC[C@]12C

• Molecular Formula:

  C26H44NNaO6S

• Molecular Weight:

  521.69

• Precautions:

  H302, H315, H319, H335

• References & Citations:

  [1]Kim SY, et al. Tauroursodeoxycholate (TUDCA) inhibits neointimal hyperplasia by suppression of ERK via PKCα-mediated MKP-1 induction. Cardiovasc Res. 2011 Nov 1;92 (2) :307-16.|[2]Qin Y, et al. Tauroursodeoxycholic Acid Attenuates Angiotensin II Induced Abdominal Aortic Aneurysm Formation in Apolipoprotein E-deficient Mice by Inhibiting Endoplasmic Reticulum Stress. Eur J Vasc Endovasc Surg. 2017 Mar;53 (3) :337-345.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category:

  Reference compound1

• Clinical Information:

  Launched

• Isoform:

  Caspase 12; Caspase 3; ERK; Human Endogenous Metabolite

• Citation 01:

  Arch Toxicol. 2025 Aug 20.|Biochem Pharmacol. 2018 Aug:154:278-292.|Biofabrication. 2021 May 5;13 (3) .|bioRxiv. 2020 Jun.|Brain Res Bull. 2020 Sep;162:73-83.|Cell Biol Toxicol. 2024 Jan 22;40 (1) :1.|Cell Prolif. 2021 Nov;54 (11) :e13133.|Cell Stress Chaperones. 2022 May;27 (3) :273-283.|Ecotoxicol Environ Saf. 2022 May 1;236:113508.|FASEB J. 2025 Jun 15;39 (11) :e70695.|FEBS Open Bio. 2020 Oct;10 (10) :2122-2136.|Fundam Clin Pharmacol. 2018 Aug;32 (4) :363-377.|Int J Mol Sci. 2023 Jul 20;24 (14) :11692.|Mater Design. 8 November 2021, 110229.|MedComm-Oncology. 2023 Feb 19.|Mol Ther. 2023 Mar 1;31 (3) :890-908.|Nat Cell Biol. 2023 May;25 (5) :726-739.|Nutrients. 2021 Dec 1;13 (12) :4343.|Oxid Med Cell Longev. 2022 Aug 31;2022:9004738.|Research Square Preprint. 2023 Oct 16.|Sci Rep. 2017 Aug 30;7 (1) :9967. |Virol J. 2025 Nov 17;22 (1) :378.|Adv Sci (Weinh) . 2021 Nov;8 (21) :e2101936.|Adv Sci (Weinh) . 2025 Feb 3:e2411719.|Am J Pathol. 2024 Jan;194 (1) :85-100.|Anim Cells Syst. 2023 Nov 27.|Appl Biochem Biotechnol. 2024 Oct;196 (10) :7362-7374.|Biochem Biophys Res Commun. 2021 Mar 12:544:44-51.|Biochem Biophys Res Commun. 2024 Apr 25:149972.|Biochem Biophys Res Commun. 2024 May 14:708:149770.|Biochem Pharmacol. 2025 Dec;242 (Pt 4) :117377.|Biochem Pharmacol. 2025 Jun:236:116868.|Biomed Pharmacother. 2019 Dec;120:109475.|Biomed Pharmacother. 2022 May 24;151:113173.|Biomed Pharmacother. 2023 Aug:164:114897.|BMC Mol Cell Biol. 2023 Mar 3;24 (1) :7.|Br J Pharmacol. 2019 Jul;176 (13) :2162-2178. |Cancer Med. 2023 Jun;12 (12) :13610-13622.|Cancers. 2020 Mar 6;12 (3) :613.|Cell Biol Toxicol. 2023 Jun;39 (3) :907-928.|Cell Biol Toxicol. 2025 Mar 7;41 (1) :56.|Cell Death Dis. 2020 Apr 24;11 (4) :279.|Cell Death Dis. 2023 Aug 15;14 (8) :524.|Cell Host Microbe. 2025 Aug 19:S1931-3128 (25) 00291-4.|Cell Rep. 2023 Dec 27;43 (1) :113591.|Cell Rep. 2025 Nov 25;44 (11) :116502.|Cell Signal. 2024 Dec 8:127:111560.|Chem Res Toxicol. 2025 Feb 17;38 (2) :314-324.|Chin Med J (Engl) . 2025 Jan 5;138 (1) :79-92.|Cytokine. 2020 Mar;127:154959.|Cytokine. 2026 Jan:197:157068.|Departamento de Biotecnología. 2020 Sep.|Diagn Microbiol Infect Dis. 2024 Aug 22;110 (4) :116500.|Ecotoxicol Environ Saf. 2024 Jan 15:270:115895.|Environ Pollut. 2025 Oct 6:127217.|FASEB J. 2025 Jun 15;39 (11) :e70715.|Food Chem Toxicol. 2018 Oct:120:253-260.|Food Chem Toxicol. 2025 Jun 4:203:115592.|Front Cell Dev Biol. 2020 May 12;8:269.|Front Pharmacol. 2021 Aug 23;12:708462.|Front Pharmacol. 2022 Sep 16;13:977622.|Gut Microbes. 2024 Jan-Dec;16 (1) :2392877.|Infect Genet Evol. 2020 Nov;85:104552.|Int Heart J. 2023 Mar 31;64 (2) :283-293.|Int Immunopharmacol. 2021 Jun:95:107519.|Int Immunopharmacol. 2025 Jan 3:147:113982.|Int Immunopharmacol. 2025 Sep 6:165:115471.|J Agric Food Chem. 2025 Aug 13;73 (32) :20235-20253.|J Agric Food Chem. 2025 Aug 6;73 (31) :19442-19459.|J Cachexia Sarcopenia Muscle. 2021 Dec;12 (6) :1553-1569.|J Cell Mol Med. 2019 Oct;23 (10) :7029-7042.|J Inflamm. 2023 Nov 1;20 (1) :36.|J Int Med Res. 2023 May;51 (5) :3000605231173272.|J Pharm Anal. 2024 Aug 22.|J Pharm Biomed Anal. 2025 Jul 15:259:116760.|J Steroid Biochem Mol Biol. 2024 Aug 13:106599.|J Trace Elem Med Biol. 2024 Aug 28:86:127512.|Life Sci. 2025 May 15:369:123526.|Nat Commun. 2025 Aug 16;16 (1) :7638.|Nature. 2025 Jul;643 (8070) :192-200.|Nutr Diabetes. 2024 Sep 13;14 (1) :75.|Nutr Metab. 2020 Jan 30;17:11.|Pharmacology. 2018 Dec 5;103 (1-2) :93-100. |Phytomedicine.2023 Sep:118:154971.|PLoS One. 2023 May 18;18 (5) :e0283943.|Redox Biol. 2023 Oct:66:102861.|Research Square Preprint. 2023 Oct 23.|Respir Res. 2025 Apr 12;26 (1) :136.|Sci Total Environ. 2024 Jul 6:174536.|Sci Total Environ. 2024 Jun 25:946:174299.

• CAS Number:

  35807-85-3